ATE414176T1 - Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene - Google Patents

Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene

Info

Publication number
ATE414176T1
ATE414176T1 AT03765758T AT03765758T ATE414176T1 AT E414176 T1 ATE414176 T1 AT E414176T1 AT 03765758 T AT03765758 T AT 03765758T AT 03765758 T AT03765758 T AT 03765758T AT E414176 T1 ATE414176 T1 AT E414176T1
Authority
AT
Austria
Prior art keywords
hsv
antigens
lymphocytes
specific
virus
Prior art date
Application number
AT03765758T
Other languages
English (en)
Inventor
David Koelle
Zhi Liu
Lawrence Corey
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of ATE414176T1 publication Critical patent/ATE414176T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
AT03765758T 2002-07-18 2003-07-18 Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene ATE414176T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39679102P 2002-07-18 2002-07-18

Publications (1)

Publication Number Publication Date
ATE414176T1 true ATE414176T1 (de) 2008-11-15

Family

ID=30770951

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08166335T ATE494907T1 (de) 2002-07-18 2003-07-18 Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten
AT03765758T ATE414176T1 (de) 2002-07-18 2003-07-18 Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08166335T ATE494907T1 (de) 2002-07-18 2003-07-18 Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten

Country Status (8)

Country Link
US (7) US7078041B2 (de)
EP (5) EP2011510B1 (de)
AT (2) ATE494907T1 (de)
AU (1) AU2003252052A1 (de)
CA (1) CA2492598C (de)
DE (2) DE60324678D1 (de)
DK (2) DK2011510T3 (de)
WO (1) WO2004009021A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL346213A1 (en) * 1998-08-07 2002-01-28 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
AU2006289514A1 (en) * 2005-09-08 2007-03-15 Mologen Ag Functional in vitro immunoassay
WO2007064859A2 (en) * 2005-11-29 2007-06-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compound and method for suppressing retroviral replication
JP5872755B2 (ja) * 2006-07-20 2016-03-01 バイカル インコーポレイテッド 抗ｈｓｖ−２ワクチン接種のための組成物および方法
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2413950A4 (de) * 2009-04-03 2013-05-01 Univ Washington Antigenes hsv-2-peptid und verwendungsverfahren dafür
CA2797937C (en) * 2009-05-22 2020-01-14 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2012074881A2 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CA2885693C (en) 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2013168978A1 (ko) * 2012-05-07 2013-11-14 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
US9938498B2 (en) 2012-05-07 2018-04-10 Nkmax Co., Ltd. Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells
EP2850431B1 (de) 2012-05-16 2018-04-18 Immune Design Corp. Impfstoffe gegen hsv-2
CN104694553B (zh) * 2013-12-05 2018-04-17 长春百克生物科技股份公司 生殖器疱疹疫苗
US20180320230A1 (en) * 2015-10-27 2018-11-08 Arizona Board Of Regents On Behalf Of Arizona State University High throughput identification of t-cell recognition antigens and epitopes
EP3519427A4 (de) 2016-09-28 2020-03-11 Genocea Biosciences Inc. Verfahren und zusammensetzungen zur behandlung von herpes
WO2019018796A1 (en) * 2017-07-21 2019-01-24 Fred Hutchinson Cancer Research Center VACCINE EPITOPES AGAINST HERPES SIMPLEX VIRUS RECOGNIZED SPECIFICALLY BY MEMORY T LYMPHOCYTES RESIDING IN FABRICS
CA3089853A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
US11608897B2 (en) 2018-08-01 2023-03-21 Eagle Industry Co., Ltd. Slide component
EP3842673A4 (de) 2018-08-24 2022-05-04 Eagle Industry Co., Ltd. Gleitelement
CN112739941B (zh) 2018-10-01 2023-11-14 伊格尔工业股份有限公司 滑动部件
WO2020085122A1 (ja) 2018-10-24 2020-04-30 イーグル工業株式会社 摺動部材
EP4198353B1 (de) 2018-11-30 2025-03-12 Eagle Industry Co., Ltd. Schiebekomponente
EP3901497B1 (de) 2018-12-21 2024-08-21 Eagle Industry Co., Ltd. Gleitkomponente
KR102610647B1 (ko) 2019-02-04 2023-12-07 이구루코교 가부시기가이샤 슬라이딩 부품
KR102639196B1 (ko) 2019-02-14 2024-02-21 이구루코교 가부시기가이샤 슬라이딩 부품
WO2020171102A1 (ja) 2019-02-21 2020-08-27 イーグル工業株式会社 摺動部品
US11892081B2 (en) 2019-07-26 2024-02-06 Eagle Industry Co., Ltd. Sliding component
US12276338B2 (en) 2020-06-02 2025-04-15 Eagle Industry Co., Ltd. Sliding component
WO2021246372A1 (ja) 2020-06-02 2021-12-09 イーグル工業株式会社 摺動部品
KR20240019290A (ko) * 2021-07-13 2024-02-14 이구루코교 가부시기가이샤 슬라이딩 부품

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0845537A1 (de) 1989-08-18 1998-06-03 Chiron Corporation Rekombinante Retroviren, die einen Prodrug exprimieren, zur Behandlung von GVhD
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
TW232710B (de) * 1991-09-13 1994-10-21 American Cyanamid Co
ATE188613T1 (de) 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
EP0714399A4 (de) * 1993-08-20 1999-01-27 Smithkline Beecham Corp Hsv-2 ul26 gen, hüllproteine, immunoassays und proteaseinhibitoren
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
GB9325496D0 (en) * 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU693437B2 (en) * 1993-12-28 1998-07-02 Chiron Mimotopes Pty Ltd T-cell epitopes
PT772619E (pt) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US5958895A (en) * 1996-10-23 1999-09-28 American Home Products Corporation DNA vaccines for herpes simplex virus
EP0948508A4 (de) * 1996-11-04 2001-11-07 Smithkline Beecham Corp Kodierungssequenzen vom herpes-simplex-virus typ 2
PL346213A1 (en) 1998-08-07 2002-01-28 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
ATE345389T1 (de) 1999-09-30 2006-12-15 Univ Washington Immunologisch relevante antigene aus herpes simplexvirus
US6375652B1 (en) * 2000-05-04 2002-04-23 Brymill Corporation Cutaneous cryosurgical clamp
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
EP1297147B8 (de) * 2000-06-29 2007-02-21 Corixa Corporation Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
WO2002056828A2 (en) * 2000-11-29 2002-07-25 University Of Rochester Helper virus-free herpes virus amplicon particles and uses thereof
US8092791B2 (en) * 2001-05-23 2012-01-10 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
EP2191845A1 (de) * 2001-07-31 2010-06-02 University of Washington Immunologisch bedeutende Herpes-simplex-virus-antigene und Verfahren für ihre Verwendung
US20030219448A1 (en) * 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases

Also Published As

Publication number Publication date
US7078041B2 (en) 2006-07-18
DK1523582T3 (da) 2009-03-02
EP1523582A2 (de) 2005-04-20
EP2263686B1 (de) 2012-12-26
US7431934B2 (en) 2008-10-07
CA2492598C (en) 2013-12-17
EP2263686A1 (de) 2010-12-22
EP2316479A3 (de) 2011-07-06
EP2865386B1 (de) 2017-07-05
CA2492598A1 (en) 2004-01-29
WO2004009021A3 (en) 2004-06-03
US7666434B2 (en) 2010-02-23
EP2011510B1 (de) 2011-01-12
EP2865386A1 (de) 2015-04-29
US20060216304A1 (en) 2006-09-28
DE60324678D1 (de) 2008-12-24
US20110135687A1 (en) 2011-06-09
EP1523582B1 (de) 2008-11-12
EP2316479B1 (de) 2014-12-03
US9675688B2 (en) 2017-06-13
US20130189294A1 (en) 2013-07-25
EP2011510A3 (de) 2009-04-08
US20160095918A1 (en) 2016-04-07
ATE494907T1 (de) 2011-01-15
US20090148468A1 (en) 2009-06-11
US20040072152A1 (en) 2004-04-15
DK2011510T3 (da) 2011-03-28
EP2011510A2 (de) 2009-01-07
AU2003252052A1 (en) 2004-02-09
EP2316479A2 (de) 2011-05-04
DE60335755D1 (de) 2011-02-24
WO2004009021A2 (en) 2004-01-29
EP2316479B8 (de) 2015-03-18
US8197824B2 (en) 2012-06-12
US9138473B2 (en) 2015-09-22
EP1523582A4 (de) 2007-02-07
US20130011425A1 (en) 2013-01-10
AU2003252052A8 (en) 2004-02-09

Similar Documents

Publication Publication Date Title
ATE414176T1 (de) Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene
NO20021479D0 (no) Immunologiske signifikante herpes simplex virus antigener og metoder for å identifisere og å bruke dem
AR020134A1 (es) Antigenos inmunologicos contra el virus herpes simplex y metodos para el uso de los mismos
EA200500733A1 (ru) Способы и продукты, относящиеся к лечению и предупреждению инфекции вируса гепатита c
WO2003011893A3 (en) Immunologically significant herpes simplex virus antigens and methods for using same
CY1105389T1 (el) Hpv-e7 ως αγωγη εναντι του ιου θηλωματων ανθρωπου
EP0726758A4 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
ATE526994T1 (de) Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
BG98522A (bg) Пептиди, индуциращи цитотоксичен т-лимфоцитен отговор на вируса на хепатит в
HUP9801266A2 (hu) Multimer, rekombináns ureázvakcina
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
PT848615E (pt) Vacinas de fiv de multiplos subtipos
BRPI0410422A (pt) materiais e processos para para imunização contra infecção por fiv
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
RU94038427A (ru) Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties